Harrow, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Harrow, Inc. (HROW) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $11.24 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-10
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $11.24M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $16.33M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $3.48M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $8.45M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $11.24M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $16.33M 10-Q · filed 2026-05-11 |
| 2025-09-30 | $3.48M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $8.45M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $12.68M 10-Q · filed 2025-05-08 |
| 2024-09-30 | $4.03M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $5.10M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $10.24M 10-Q · filed 2024-05-13 |
| 2023-09-30 | $2.46M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $5.85M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $8.78M 10-Q · filed 2023-05-11 |
| 2022-09-30 | $523.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $795.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.19M 10-Q · filed 2022-05-05 |
| 2021-09-30 | $44.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $110.00K 10-Q · filed 2021-08-10 |
| 2021-03-31 | $149.00K 10-Q · filed 2021-05-11 |
| 2020-09-30 | $47.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $85.00K 10-Q · filed 2020-08-10 |
| 2020-03-31 | $145.00K 10-Q · filed 2020-05-11 |
| 2019-09-30 | $55.00K 10-Q · filed 2019-11-13 |
| 2019-06-30 | $128.00K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $188.00K 10-Q · filed 2019-05-09 |
| 2018-12-31 | $244.00K 10-K · filed 2019-03-12 |
| 2018-09-30 | $61.00K 10-Q · filed 2018-11-13 |
| 2018-06-30 | $113.00K 10-Q · filed 2018-08-06 |
| 2018-03-31 | $168.00K 10-Q · filed 2018-05-15 |
| 2017-09-30 | $90.00K 10-Q · filed 2017-11-14 |
| 2017-06-30 | $182.00K 10-Q · filed 2017-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |